Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $7.7650 (-7.78%) ($7.7650 - $7.7650) on Tue. Aug. 16, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.25% (three month average) | RSI | 60 | Latest Price | $7.7650(-7.78%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 0.9% a day on average for past five trading days. | Weekly Trend | TGTX advances 15.4% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) ICLN(89%) LIT(87%) XHB(87%) EWP(83%) XBI(81%) | Factors Impacting TGTX price | TGTX will decline at least -3.625% in a week (0% probabilities). UUP(-46%) USO(-9%) XOP(3%) TBT(-48%) XLE(3%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.625% (StdDev 7.25%) | Hourly BBV | -1.8 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $7.99(-2.82%) | 10 Day Moving Average | $7.4(4.93%) | 20 Day Moving Average | $6.85(13.36%) | To recent high | -7.8% | To recent low | 107.9% | Market Cap | $983m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |